Moderna expands mRNA cancer pipeline after personalized vaccine hits Phase 3 endpoint
AI Summary- Moderna is expanding its mRNA pipeline into universal cancer vaccines and in vivo CAR-T.
- mRNA-4359 is in Phase 2 trials for melanoma and non-small cell lung cancer.
- Intismeran Autogene and Keytruda met a Phase 3 primary endpoint in high-risk melanoma.